{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:53:43Z","timestamp":1788497623114,"version":"build-2803163510"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["080716"],"award-info":[{"award-number":["080716"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0225381","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T19:47:55Z","timestamp":1574365675000},"page":"e0225381","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey"],"prefix":"10.1371","volume":"14","author":[{"given":"Andrea","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Pezzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"D\u00f6ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-8551","authenticated-orcid":true,"given":"Francesca","family":"Incardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lengauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Sch\u00fclter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mieke","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Geretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the EucoHIV Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"12","key":"pone.0225381.ref001","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nbt1371","article-title":"Bioinformatics prediction of HIV coreceptor usage","volume":"25","author":"T Lengauer","year":"2007","journal-title":"Nat Biotechnol"},{"issue":"2","key":"pone.0225381.ref002","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/QAD.0b013e32834113f9","article-title":"Genotypic tropism testing: evidence-based or leap of faith?","volume":"25","author":"PR Harrigan","year":"2011","journal-title":"AIDS"},{"issue":"14","key":"pone.0225381.ref003","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e32830ebcd4","article-title":"Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism","volume":"22","author":"S Raymond","year":"2008","journal-title":"AIDS"},{"issue":"7","key":"pone.0225381.ref004","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkq137","article-title":"High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists","volume":"65","author":"E Secl\u00e9n","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"pone.0225381.ref005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1742-4690-7-56","article-title":"Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping","volume":"7","author":"MC Prosperi","year":"2010","journal-title":"Retrovirology"},{"issue":"2","key":"pone.0225381.ref006","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/JCM.01118-06","article-title":"Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model","volume":"45","author":"K Skrabal","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"2","key":"pone.0225381.ref007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/dkq458","article-title":"Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment","volume":"66","author":"L Vandekerckhove","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0225381.ref008","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1310\/hct1103-125","article-title":"Efficacy and safety of maraviroc versus efavirenz, both with zidovudine\/lamivudine: 96-week results from the MERIT study","volume":"11","author":"J Sierra-Madero","year":"2010","journal-title":"HIV Clin Trials"},{"issue":"5","key":"pone.0225381.ref009","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/QAD.0000000000000131","article-title":"Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings","volume":"28","author":"DA Cooper","year":"2014","journal-title":"AIDS"},{"issue":"5","key":"pone.0225381.ref010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/QAI.0b013e3181ee3d82","article-title":"Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2","volume":"55","author":"WD Hardy","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"pone.0225381.ref011","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/QAD.0b013e3283372d76","article-title":"Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience","volume":"24","author":"S Nozza","year":"2010","journal-title":"AIDS"},{"issue":"1","key":"pone.0225381.ref012","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1179\/1528433614Z.0000000002","article-title":"The maraviroc expanded access program\u2014safety and efficacy data from an open-label study","volume":"16","author":"A Lazzarin","year":"2015","journal-title":"HIV Clin Trials"},{"issue":"2","key":"pone.0225381.ref013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP2817","article-title":"Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy","volume":"20","author":"L Waters","year":"2015","journal-title":"Antivir Ther"},{"issue":"1","key":"pone.0225381.ref014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/aid.2015.0386","article-title":"Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice","volume":"33","author":"M Saumoy","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"pone.0225381.ref015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1089\/aid.2015.0016","article-title":"The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age","volume":"31","author":"JR Blanco","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"pone.0225381.ref016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2015.05.001","article-title":"Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes","volume":"120","author":"JM Llibre","year":"2015","journal-title":"Antiviral Res"},{"issue":"7","key":"pone.0225381.ref017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/hiv.12129","article-title":"Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting","volume":"15","author":"J Mac\u00edas","year":"2014","journal-title":"HIV Med"},{"issue":"6","key":"pone.0225381.ref018","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/jac\/dks539","article-title":"Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial","volume":"68","author":"A Bonjoch","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"pone.0225381.ref019","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1473-3099(10)70319-4","article-title":"European Consensus Group on clinical management of tropism testing. European guidelines on the clinical management of HIV-1 tropism testing","volume":"11","author":"LP Vandekerckhove","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"pone.0225381.ref020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3851\/IMP1759","article-title":"Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","volume":"16","author":"JM Schapiro","year":"2011","journal-title":"Antiviral Therapy"},{"issue":"10","key":"pone.0225381.ref021","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40266-013-0107-7","article-title":"Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals","volume":"30","author":"L Ghidei","year":"2013","journal-title":"Drugs Aging"},{"issue":"9","key":"pone.0225381.ref022","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1093\/jac\/dkw167","article-title":"Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients","volume":"71","author":"L Bocket","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0225381.ref023","first-page":"3087","article-title":"Integrase Resistance Study Group in Spain (INI-VAIN Study Group); Integrase Resistance Study Group in Spain INI-VAIN Study Group. Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences","volume":"70","author":"JR Santos","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"15","key":"pone.0225381.ref024","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","article-title":"Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV\/r monotherapy in HIV: the role of compartment and CD4-nadir","volume":"24","author":"C Gutmann","year":"2010","journal-title":"AIDS"},{"key":"pone.0225381.ref025","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1086\/587660","article-title":"The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen","volume":"46","author":"L Waters","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0225381.ref026","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/cir493","article-title":"Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc","volume":"53","author":"LC Swenson","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0225381.ref027","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of Protease Inhibitor\/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis","volume":"66","author":"AJ Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"16","key":"pone.0225381.ref028","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/QAD.0000000000000810","article-title":"Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery","volume":"29","author":"AR Cillo","year":"2015","journal-title":"AIDS"},{"issue":"3","key":"pone.0225381.ref029","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jac\/dkr493","article-title":"Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800\/100 mg","volume":"67","author":"C Okoli","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"pone.0225381.ref030","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A4001029 Study Group. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1","volume":"199","author":"M Saag","year":"2009","journal-title":"J Infect Dis"},{"issue":"7","key":"pone.0225381.ref031","doi-asserted-by":"crossref","first-page":"e0132430","DOI":"10.1371\/journal.pone.0132430","article-title":"Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial","volume":"10","author":"MIRS study group","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"pone.0225381.ref032","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/cid\/ciw737","article-title":"Swiss HIV Cohort Study. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1","volume":"64","author":"J Bader","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0225381.ref033","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jis376","article-title":"A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4\u207a T-cell recovery despite sustained virologic suppression: ACTG A5256","volume":"206","author":"TJ Wilkin","year":"2012","journal-title":"J Infect Dis"},{"issue":"21","key":"pone.0225381.ref034","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1161\/CIRCULATIONAHA.113.001278","article-title":"Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice","volume":"127","author":"S Cipriani","year":"2013","journal-title":"Circulation"},{"key":"pone.0225381.ref035","unstructured":"Rossetti B, Gagliardini R, Sterrantino G et al. The effect of switching to Darunavir\/r + Maraviroc dual therapy in virologically suppressed patients on the progression of liver fibrosis: findings from a randomized study. 9th Italian Conference on AIDS and Antiviral Research, Siena, Italy, June 12\u201314 2017, P6"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T23:01:19Z","timestamp":1612479679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225381"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0225381","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]}}}